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  Breast cancer is a heterogeneous disease that is the second leading 
cause of cancer related deaths in women.  Cancer is defined as abnormally heightened 
proliferation.  In order for gene transcription and eventual translation to occur to drive the 
cell cycle to generate more cells, DNA must be uncoiled from nucleosomes by histone 
acetylation complexes.  One of the key evolutionarily conserved components of these 
HAT complexes is alteration/deficiency in activation 3 (ADA3).  In addition to the role in 
histone acetylation, this protein also functions as a coactivator for nuclear hormone 
receptors.  Recent findings indicated that nuclear Ada3 correlates with ER+ breast 
cancers and a favorable survival, while cytoplasmic (overexpression) Ada3 correlates 
with ErbB2+ and EGFR+ breast cancers and a poor survival. 
 My thesis work focused on the role of Ada3 knockdown and overexpression on 
cellular proliferation in human derived cell lines.  We showed knockdown of ADA3 in 
immortal hMECs led to inhibition of cell cycle progression, decrease in cyclin B, c-myc or 
H3K56 levels, and increase in p27 protein. In contrast, ADA3 overexpression in two 
immortal hMECs and two ER+ breast cancer cell lines enhanced proliferation.  Cell cycle 
analyses showed increased cyclin B and decreased p27 upon ADA3 overexpression. 
Decreased p27 levels were due to increased turnover of p27 protein.  Furthermore, 
ADA3 overexpression led to increased mRNA levels of early response genes c-fos, 
EGR1, and c-myc. Analysis of a large cohort of ER+ breast cancer tissue specimens 
showed a subset of ER+ tumors express higher levels of ADA3 and these tumors also 
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express higher levels of c-myc (p <0.0001).  Overexpression enhances proliferation 
through increasing c-myc expression, and expression patterns with ADA3 high/low and 
c-myc high/low can divide patients into four subgroups with significant differences in 
molecular biomarkers’ status and clinical-pathological parameters. Thus, we suggest 
ADA3 nuclear overexpression in ER+ breast cancer patients can serve as a biomarker to 
predict tumor progression.  In order to better decipher the role of ADA3 in the murine 
mammary gland I generated a tamoxifen inducible deletion mouse model for use in 
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1.  INTRODUCTION 
 
Gene transcription is an integral part of all cellular processes, as proper cellular function 
depends on its final downstream products, proteins.  However, genomic DNA in 
eukaryotic cells exists in multiple ordered states ranging from the highly compacted 
chromosome to the transcriptionally accessible double helix.  As a result of this 
compaction, most chromatin is not transcriptionally active and is referred to as 
heterochromatin.  In order for cells to begin the transcriptional process to generate 
mRNA which is then translated into new proteins, the highly ordered DNA must made 
more readily accessible to the transcriptional machinery by being converted into the 
active euchromatin.  Therefore it is necessary that the DNA be uncoiled from the 
nucleosome units composed of an octamer of histones around which it is wrapped 
(Luger et al., 1997).  The histone octamer is composed of two copies of each of the four 
primary histone proteins: H3, H4, H2A, and H2B.  This central set of proteins provides 
the basic structural unit for the compaction of DNA.   
 The post-translational modification of these eight core proteins allow the 
conversion of heterochromatin to euchromatin and thus grant the transcriptional 
machinery access to the DNA (Strahl & Allis, 2000).  The key post-translational 
modification responsible for this interconversion is acetylation.  Without the addition of 
these C2H3O functional groups to the core histones, chromatin would remain compact 
and inaccessible to DNA binding proteins (Strahl & Allis, 2000).  Consequently, the 
process of histone modification is widely conserved across all eukaryotes, making it of 
great interest to biologists studying both normal and cancerous cells (Grunstein, 1997).  
An ever changing state of acetyl group addition and removal exists governed by 
opposing proteins named histone acetyltransferases (HATs) and histone deacetylases 
(HDACs) (Kouzarides, 1999).  Both of these post-translational modification causing 
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proteins function in concert with multiple other proteins in complexes, thus forming HAT 
and HDAC complexes that can work in governing gene transcription.  Of greater interest 
to us are the HAT complexes, as they contain alteration/deficiency in activation 3 (Ada3), 
one of the primary proteins studied by our lab.  
 
1.1 EVOLUTIONARY CONSERVATION OF ADA3 
 
 HAT containing protein complexes usually consist of multiple subunits that are 
evolutionarily conserved (Lee & Workman, 2007).  The HAT protein complex named 
alteration/deficiency in activation, or ADA complex, was first discovered in yeasts during 
the 1990s.  The ADA complex is composed of the adaptor proteins Ada2 and Ada3 in 
addition to ADA HAT complex component 1(AHC1), and the core histone acetylase 
general control nonderepressible 5 (Eberharter et al., 1999).  The primary function of the 
adaptor proteins is to act as binding partners to keep the different subunits of the 
complexes in close proximity through protein binding motifs.  The proteins of the Ada 
family (Ada1-5) were originally found to be involved in resistance when mutated (Marcus 
et al, 1994; Marcus et al., 1996).  Specifically, the Ada3 protein was initially discovered 
due to it promoting resistance to toxicity induced by exposure to GAL4-VP16 (Pina, et 
al., 1993).  The ADA complex primarily functions in the regulation of gene transcription in 
yeasts (Grant, et al, 1997; Grant, et al, 1998).  A subset of these ADA complex 
components (Ada2, Ada3, and Gcn5) functions in two other yeast complexes named the 
Spt-Ada-Gcn5 acetyltransferase complex and the SAGA-like (SLIK) complex to promote 
transcription (Grant, et al 1997; Pray-Grant et al, 2002).  This is done by recruiting RNA 
polymerase II to all active gene promoters (Bonnet et al, 2014).  The evolutionary 
importance of these subunits continues into mammalian cells where they form the 
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homologous Spt3/Taf9/Gcn5 (STAGA) complex, as well as TBP-free TAF complex 
(TFTC), and Ada2a-containing (ATAC) complex (Lee & Workman, 2007).   
 Within mammalian cells the HAT containing complexes are much more complex 
than in the yeast counterparts.  Gcn5 was the core HAT in yeasts; however as the 
complexes proceed up the evolutionary ladder, HATs can work singly or in concert with 
one another.  Such examples of mammalian HATs include p300, Tip60, p300/CBP-
associated factor (PCAF), and CREB-binding protein (CBP) (Lee & Workman, 2007; 
Nagy & Tora, 2007).  The Ada3 adapter remains, however the Ada2 adapter has a pair 
of homologs known as Ada2a and Ada2b with different functions (Kusch, et al, 2003), 
leading to more complex and varied HAT complexes in higher eukaryotes.   
 
1.2 ADA3 COMPLEXES AND HISTONE ACETYLATION 
 
 Histone acetylation leading to changes in chromatin structure is critical for the 
transcriptional machinery to gain access to DNA.  As such, the HAT complexes play a 
crucial role in this loosening of the highly ordered chromatin.  The yeast ADA complex, 
through Gcn5, controls histone acetylation levels of multiple gene promoters important to 
the cell (Grant et al, 1998).  However without both Ad2 and Ada3, Gcn5 cannot properly 
acetylate histones to unwind DNA from the nucleosomes (Balasubramanian et al, 2002).  
These three proteins also form the core of the yeast SAGA complex, which was 
previously mentioned as an important HAT complex within yeast cells (Balasubramanian 
et al, 2002).  Histone H3 has been shown to be the most favored target for ADA complex 
acetylation, with modifications added to lysines 9, 14, and 18 (Balasubramanian et al, 
2002).  Additionally, they found that in order for Gcn5 to acetylate nucleosomes, Ada3 
must be present and this process is augmented by the presence of Ada2 
(Balasubramanian et al, 2002).  In the mammalian STAGA complex, Gcn5, in concert 
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with Ada3 and Ada2b, has been found to acetylate nucleosomes.  However, when 
Ada2b and Ada3 were absent, acetylation was suboptimal (Gamper et al, 2009).  When 
Ada2a was substituted for Ada2b, the complex was able to form, but acetylation did not 
occur, thus demonstrating that the pair of Ada2 homologs has separate functions in 
mammalian cells, just as there are separate functions in Drosophila (Gamper et al, 
2009).  When Ada2a is deleted in Drosophila there is no change in the levels of 
acetylation of H3K9 or H3K14 controlled by Ada2b (Pankotai et al, 2005).  When Ada3 is 
deleted in Drosophila embryo viability is greatly decreased (Grau et al, 2008).  Building 
upon this, when Ada3 is deleted in mammalian cells, the acetylation levels of multiple 
lysine residues are affected.  These include H2AK5, H2BK5, H3K9, H3K56, and H4K8 
(Mohibi, et al, 2012).  Thus when any members of this core complex are downregulated 
the ability of a cell to properly acetylate nucleosomes to allow the subsequent 
transcription of DNA is greatly reduced.  
 Histone acetylation typically occurs concurrently with the remodeling of chromatin 
in order for proteins that interact with DNA to gain access to it.  The HAT complexes 
work with Switch/sucrose nonfermentable (SWI/SNF) to remodel chromatin by displacing 
nucleosomes to make DNA more accessible for transcriptional initiation (Collingwood et 
al, 1999).  Chromatin remodeling governed by nucleosome sliding occurs at promoter 
sites or sites of DNA damage and is controlled by the SWI/SNF complex (Martens & 
Winston, 2003).  Recruitment of this complex is thought to coincide with SAGA mediated 
histone acetylation to displace nucleosomes for promoter accessibility (Mitra, et al, 2006; 
Chandy et al, 2006).  In yeast, Gcn5 mediated acetylation of the Snf2 subunit controls 
the interaction of SWI/SNF with histones (Kim et al, 2010).  Thus, chromatin remodeling 
complexes are dependent upon HAT complexes to carry out proper structural changes 




1.3 ADA3 FUNCTIONS AS A CO-ACTIVATOR FOR NUCLEAR HORMONE 
RECEPTORS 
 In general, for nuclear receptors (NRs) to function they bind their respective 
ligands and translocate to the nucleus to initiate target gene transcription.  The level of 
gene expression is governed by the specific coregulators with which the NR interacts 
(McKenna & O’Malley, 2002).  Coregulators which promote target gene expression are 
considered co-activators, while ones that impede expression are considered co-
repressors.  The basic functional structure used by coactivators to interact with NRs is 
through a leucine (L) rich helical domain commonly called an LXXLL motif, where X in 
any amino acid that binds the NR ligand binding domain (He & Wilson, 2003).   Ada3 is 
such a protein containing this LXXLL motif, and functions as a coactivator. 
 The role of Ada3 as a coactivator was first discovered in yeasts expressing 
exogenous nuclear receptors.  The complete yeast ADA complex was found to 
transactivate the glucocorticoid receptor, and ablation of Ada3 led to greatly reduced 
transactivation (Henriksson, et al, 1997).  It was later found that yeast Ada3 interacts 
with estrogen receptor alpha (ERα), thyroid hormone receptor alpha (TRα), retinoid X 
receptor alpha, (RXRα), but not with retinoic acid receptor alpha (RARα) (vom Baur et al, 
1998).  This led to earlier work performed in our laboratory where it was found that Ada3 
serves as a coactivator for ERα and RXRα, leading to increased levels of the respective 
target genes as well as increased transactivation potential (Zeng et al, 2002; Meng et a;, 
2004; Germaniuk-Kurowska et al, 2007).  Later work by other researchers found that the 
LXXLL motifs present within Ada3 do indeed interact with the RAR receptor (Let et al, 
2010).  This work demonstrates that the coactivator function of Ada3 is very important to 
nuclear receptor target gene transcription.  Of great interest to our lab is the interaction 
of Ada3 with the signaling of the estrogen receptor.   
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 Estrogen receptor alpha (ERα), a 66kDa protein, is composed of four primary 
domains and is a member of the steroid hormone receptor family.  The amino terminus 
of ER contains the activation functions (AF) domain AF-1 and it is constitutively active in 
the absence of ligand.  AF-1 is subsequently followed by a DNA binding domain, a 
hinge/nuclear localization region, and the ligand binding domain/AF-2 region that is only 
activated when bound by estrogen.  The phosphorylation of ER on serine 167 in the AF-
1 domain by AKT following growth factor signaling leads to ER activation and 
dimerization (Osborne et al., 2001).  Additionally, phosphorylation of serine 118, another 
important serine residue for ER activation, is mediated by MAPK signaling during 
estrogen stimulation (Chen et al., 2002).  Two truncation mutants exist that lack the AF-1 
domain, ERα-46 and ERα-36, though the role of these in breast cancer is not well 
characterized (Nilsson et al., 2001).  Interestingly, the truncation mutant ERα-36, which 
lacks the AF-1 domain as well as part of the LBD/AF-2 domain, has primarily been 
identified as part of the cell membrane in patient samples and implicated in anti-estrogen 
resistance (Shi et al., 2009).  Signaling by ER is directed by the AF domains and can be 
subdivided into four major types, three dependent on and one independent of estrogen 
stimulation.  The direct classical ligand dependent ER signaling pathway consists of 
estrogen binding the receptor in the cytoplasm, dimerizing with a second receptor, and 
translocating to the nucleus to bind estrogen response elements (EREs).  Nuclear 
receptor coactivators function in transcriptional activation by linking receptors, chromatin 
remodeling, and the transcriptional machinery together (Collingwood et al., 1999.)  
Active ER dimers in the presence of estrogen recruit histone acetyltransferases and 
coactivators for chromatin remodeling and transcription of ER target genes such as the 
progesterone receptor, Cyclin D, c-myc, pS2, and cathepsin D (Lin et al., 2004; Heldring 
et al., 2007; Thomas & Gustafsson, 2011).  One well defined family of NRCs is the p160 
family, composed of the steroid receptor coactivators 1-3.  SRC-3, a coactivator well 
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characterized by the O’Malley lab, has been shown to bind ER and histone 
acetyltransferases in the presence of estrogen stimulation to enhance transcription of 
ER target genes during normal development as well as during the progression of breast 
and other cancers (Xu et al., 2009.) Our laboratory has shown through in vitro 
experiments that the protein alteration/deficiency in activation 3 (Ada3) binds to ER 
regardless of estrogen stimulation.  Further examination of Ada3 and ER interactions 
revealed Ada3 to be a coactivator necessary for ER directed gene transcription (Meng et 
al., 2004).  Successive knockout studies by our lab found that Ada3 is required for 
histone acetyltransferase (HAT) recruitment to estrogen dependent promoters and 
estrogen mediated breast cancer cell proliferation (Germaniuk-Kurowska et al., 2007).  
Recently, our Ada3 coactivator and HAT complex interaction findings have been 
reproduced in cell free systems by the O’Malley lab (Foulds et al. 2013).  Another 
member of the p160 family, SRC-1, functions as a coactivator in second type of estrogen 
dependent signaling (Xu et al., 2009.)  This form of signaling transpires following ligand 
induced receptor dimerization after which the ER dimer interacts with general 
transcription factors that tether it to DNA to induce transcription at sites other than EREs.  
ER associates with the transcription factors Fos/Jun to facilitate binding to the non-ERE 
AP-1 sites which are responsible for the expression of genes such as insulin like growth 
factor 1 (IGF-1) and collagenase (Hall et al., 2001; Kushner et al., 2000).  Insulin 
modulated signaling has been found to synergize with ER signaling when ER causes an 
upregulation of IGF-1R and its downstream pathway components (Lanzino et al., 2008).  
The third method of estrogen dependent signaling requires ER to bind estrogen in the 
cytoplasm to activate second messengers and induce ion channel alterations, nitric 
oxide synthesis, or phosphorylation of transcription factors that directly bind DNA (Hall, 
et al., 2001).  Lastly, ligand independent ER signaling involves the activation of IGFR or 
EGFR by their respective growth factors to activate ERK and AKT kinases which in turn 
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phosphorylate ER.  This then activates ER mediated transcription (Thomas & 
Gustafsson, 2011).  Of these four types of ER directed signaling, only non-genomic 
signaling mediated by phosphorylated transcription factors does not require coactivators, 
denoting the importance of coactivators in signaling events.  The classical ligand 
dependent ER signaling pathway is potentially the most important to our laboratory due 
to Ada3 being defined as a coactivator for ER.  The myriad of ER signaling methods is 
complex; however, their overall goal is to activate gene transcription by recruiting the 
transcriptional machinery to chromatin that was made accessible by HAT complexes.   
 
1.4 ADA3 AND THE CELL CYCLE 
 
 It is well known that eukaryotic cells must pass through the G1, S, G2, and M 
phases of the cell cycle in order to undergo cell division.  Progression through these 
phases is tightly controlled and regulated by many interacting proteins (Schafer, 1998).   
G1 is the first and longest phase of the cell cycle during which the cell prepares for 
division by ensuring conditions are favorable for division.  During transition out of G1 and 
into the S phase, cyclin D binds cyclin dependent kinase (Cdk) 2/4 to phosphorylate 
retinoblastoma (Rb) causing the release of the transcription factor E2F1.  E2F1 
stimulates the transcription of multiple genes involved in the cell cycle and proliferation, 
during which it uses GCN5 and TRRAP as cofactors (Lang et al., 2001).  Ablation of 
TRRAP, a protein also known to interact with GCN5, has been shown to alter cell cycle 
progression (Herceg et al., 2001).    One E2F1 target gene, cyclin E, drives the transition 
from G1 to S phases.  Recently, after a detailed analysis using conditional deletion in a 
MEF system, our lab found that Ada3 regulates progression of the cell cycle from G1 to 
S phase through a c-myc-Skp2-p27 mechanism (Mohibi et al, 2012).  ER mediated 
signaling stimulates SKP2, an E3 ubiquitin ligase, to transactivate E2F1 to amplify cyclin 
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E production (Zhou et al., 2014), thus this mechanism could function in cancer cells.   
Increases in cyclin E induce Rb hyperphosphorylation and subsequently lead to Rb 
deactivation, allowing the cell to continue through the cell cycle.  When Ada3 is deleted 
the levels of phospho-Rb are decreased (Mohibi et al, 2012).  However, Rb 
phosphorylation status is not the only hurdle in the early stages of cell cycle progression 
to the S phase.   The tumor suppressor p27 inhibits cyclin D and the cyclin D/ Cdk4 
complex from phosphorylating Rb until the levels of the cyclin E/Cdk2 complex are high 
enough to induce ubiqutination of p27, causing degradation. Of note, Ada3 ablation 
causes an increase in the stability of p27 leading to an inhibition of the cell cycle via the 
aforementioned pathway, but when p27 is removed the cell cycle progression is partially 
rescued (Mohibi et al, 2012).   
 Interestingly, p27 ablation positively affects estradiol mediated ER target gene 
transcription while overexpression of p27 negatively regulates ER mediated transcription 
by sequestering ER to the cytoplasm and by interfering with ER/ cyclin D interactions 
that initiate the cell cycle, thus the levels of p27 influence transcription with respect to ER 
mediated transcription (Jeon, et al., 2012).  During DNA synthesis in the S phase, HAT 
complexes acetylate nucleosomal histones to modify the chromatin structure to allow 
transcriptional factors to gain access to synthesize specific genes.  Post replication, the 
G2 phase begins during which the cell prepares for M phase or mitosis, by transcribing 
mitotic genes that are made accessible by HAT complexes.  Our lab recently found that 
Ada3 interacts with centromere protein B (CENP-B).  The Once these proteins are fully 
synthesized, chromosomes replicated in S phase are equally divided between the 
daughter cells.  However, if Ada3 is deleted from cells chromosomes cannot properly 
segregate, thus leading to an increase in anaphase bridging (Mohibi et al, 2015).  
Following the completion of accurate division, the cells return to the G1 phase to await 
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stimulation by growth factors to begin preparations for further divisions.  However, when 
the cell cycle goes unchecked and cells proliferate out of control cancer can develop. 
 
1.5 ADA3 AND CANCER 
 
 While ADA3 must be important in several cancers, our research is particularly 
focused on breast cancers and therefore we have analyzed role of ADA3 in breast 
cancers.  Breast cancer is a heterogeneous disease that is the second leading cause of 
cancer related deaths in women.   Historically breast cancer was solely classified by 
histological features and hormone receptor expression (Schnitt, 2010; Ignatiadis & 
Sotiriou, 2010).  Histological classification can be split between invasive and in situ with 
each being subdivided further by growth and structure characteristics (Malhotra et al., 
2010).  Despite these histological divisions, treatment regimens were mainly generalized 
based upon the estrogen receptor (ER), progesterone receptor (PR), and HER2 receptor 
status.  In the past 15 years these two main forms of identification have been joined by a 
third type of stratification: gene expression profiling.  Largely due to the work of Perou 
and colleagues we now know there are six molecularly different subtypes of breast 
cancer, each with a different gene profile (Perou et. al, 2000).   These subtypes include 
luminal A (50-60%), luminal B (10-20%), HER2+/ER- (10-15%), basal-like (10-20%), 
claudin low (12-14%), and normal breast-like (5-10%) (Eroles et al, 2012). This division 
into subtypes has greatly helped to stratify patients for more helpful therapeutic 
intervention and prediction of potential causes of future disease relapse.  Each subtype 
has intrinsic differences in susceptibility to chemotherapy and anti-endocrine therapy.  
While basal-like breast cancer may be the most difficult to treat due to a lack of 
targetable receptors, the most prevalent subtype of breast cancer is luminal A, 
expressing both the estrogen receptor (ER) and its transcriptional target, the 
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progesterone receptor (PR), while lacking the HER2 receptor tyrosine kinase.  Luminal A 
tumors are susceptible to anti-estrogen therapy, the accepted standard of treatment for 
such breast cancers in premenopausal women.  Resultantly these drugs are 
administered to kill tumor cells in addition to surgical removal of the tumor.  In some 
cases anti-estrogens are administered after surgery as an adjuvant to limit potential 
recurrence if node status, tumor size, stage, and genomic prediction arrays warrant it 
(Ignatiadis & Sotiriou, 2010).  The compounds administered to patients during anti-
estrogen therapy function to antagonize growth by competitively inhibiting the binding of 
estrogen with ER to interfere with signaling pathways and target gene transcription that 
direct cellular proliferation and cell cycle progression.  The luminal B subtype of ER+ 
breast cancer can be PR- and even HER2+.  This second type of luminal tumors have a 
higher proliferative marker staining (Ki67) than their luminal A counterparts (Ignatiadis & 
Sotiriou, 2010).  Combining the more heterogeneous receptor profile of the luminal B 
subtype with luminal A demonstrates that approximately 70% of all breast cancers are 
ER+, thus since Ada3 functions as an ER coactivator it could have an important role in 
nearly 3/4 of breast cancer.   
Previously we demonstrated that ADA3 binds to ER.  Through the use of 
sedimentation gradients and co-immunoprecipitation experiments it was determined that 
Gcn5, PCAF, and p300 all associate with ER and ADA3.  ChIP analysis demonstrated 
that ADA3 knockdown with shRNA led to decreased Gcn5, p300, and PCAF at active 
pS2 promoter sites in the ER+ MCF-7 and ZR-75-1 cell lines.  Subsequent analysis 
found that ADA3 knockdown in these ER+ cell lines led to decreased estrogen 
dependent proliferation both in culture dishes and in Matrigel.  Thus demonstrating 
ADA3 was integral to the transcription of ER target genes and estrogen dependent 
breast cancer cell proliferation. 
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Recent work performed by our lab was able to determine the effect of Ada3 
expression on the different subtypes of breast cancer.  Due to Ada3 being a nuclear 
protein, localization into the cytoplasm would denote a form of overexpression or 
mislocalization.  Mirza et al found that cytoplasmic/overexpression of Ada3 correlated 
with poor prognosis and EGFR+/ErbB2+ breast cancer patients; while nuclear Ada3 
correlates with a good prognosis and ER+ breast cancer patients (2012).     
Recent unpublished data from our laboratory demonstrates nuclear 
overexpression of ADA3 is seen in a subset of ER+ breast cancers; these tumors also 
overexpress c-myc, as well as express high levels of the proliferation marker Ki67.    
Interestingly, c-myc is observed to be amplified in 15% of breast cancers (Xu et al, 
2010).  When overexpressed, prognosis of patients is decreased and is connected to the 
appearance of endocrine therapy resistance (Xu et al, 2010; Dang, 2012; Wolfer et al, 
2010).  ER+ breast cancer cell lines long term deprived of estrogen develop altered 
proliferative abilities and an altered gene expression profile that correlates with myc 
mediated endocrine therapy resistance (Miller, T.W. et al, 2011.).    During periods of low 
nutrient availability, therapy resistant cell lines with increased c-myc expression can 
metabolize glutamine and glucose (Shajahan-Haq, et al, 2014).  C-myc was additionally 
seen to independently predict distant metastases-free survival in endocrine therapy 
treated luminal A patients who were lymph node positive (Green et al, 2016).  Taken 
together these results suggest the ADA3 complex regulates c-myc mediated proliferation 
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Coordination of cell cycle progression with chromosomal duplication maintains genomic 
stability; a critical cancer-associated trait (Schvartzman et al, 2010).  Deregulated cell 
cycle components have now also emerged as key biomarkers and therapeutic targets in 
cancer (Lapenna & Giordano, 2009). Thus, a better understanding of cell cycle 
machinery and its aberrations in cancer are of fundamental importance in cell and 
cancer biology.  Among cell cycle regulatory pathways, histone acetylation has emerged 
as a conserved mechanism that is invariably altered in cancer (Kouzarides, 1999)as it 
plays key roles in chromatin assembly, accessibility to transcription and replication 
machineries, and genome stability (Peng & Karpen, 2007).  Steady-state levels of 
histone acetylation and its dynamic changes represent a balance between HATs and 
HDACs (Kouzarides, 2007).  Given the therapeutic efficacy of relatively general HDAC 
inhibitors in cancers (Johnstone, 2002), it is likely that more targeted agents to alter 
acetylation in cancer cells will provide improved anticancer strategies.  Despite these 
promising prospects, the physiological regulation of histone acetylation in relation to cell 
cycle progression in epithelial cells, precursors of most human cancers, remains 
incomplete.  
Breast cancer is the single most common malignancy in women (Malhotra et al, 2010). 
Towards identifying novel regulators of cell cycle in hMECs, we previously used the 
dominant hMEC-immortalizing HPV16 E6 oncogene and identified ADA3 as a E6-
binding protein (Kumar et al, 2002) and showed its coactivator function for p53 (Kumar 
et al, 2002; Nag et al, 2007), retinoic acid (Zeng et al, 2002), and estrogen receptors 
(ER)  (Meng et al, 2004; Germaniuk-Kurowska et al, 2007) transactivation; others 
showed its role in androgen receptor (Zhao et al, 2008). We observed in breast cancer 
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cells ADA3 is in a large complex that include components of the yeast Ada complex 
(Ada2, Ada3 and GCN5, a HAT) but also other cell cycle- and cancer-associated HATs, 
p300 and PCAF (Germaniuk-Kurowska et al, 2007).  ADA3 is also a component of other 
HAT complexes such as the Spt3/Taf9/Gcn5 acetyltransferase complex (STAGA) and 
the Ada2a-containing (ATAC) complex (Spedale et al, 2012). We demonstrated that 
ADA3 is essential for p300-mediated p53 acetylation (Nag et al, 2007). Together, these 
studies suggested a potentially important role of ADA3 in breast cancer.  
To explore the physiological function of ADA3, we engineered Ada3 fl/fl mice that 
showed germline homozygous deletion of Ada3 was early embryonic lethal (Mohibi et al, 
2012).  The most dramatic result of conditional deletion of Ada3 in Ada3 fl/fl MEFs was 
defects in cell cycle progression, including delayed G1 to S transition, mitotic 
catastrophe, and defective cytokinesis (Mohibi et al, 2012), suggesting lack of 
coordination between DNA replication and subsequent cytokinesis, a precursor for 
accumulation of DNA damage and genomic instability (Blow & Tanaka, 2005).  Indeed, 
Ada3-null MEFs exhibited increased basal levels of DNA damage response, a delay in 
the repair of γ-irradiation-induced DNA damage; and increased chromosomal 
aberrations that increased further upon DNA damage (Mirza et al, 2012), suggesting 
critical roles of histone acetylation in cell cycle-associated transcription, chromatin 
assembly around newly-synthesized DNA; resolution of stalled replication forks and 
replication-coupled DNA damage repair (Lukas et al, 2011; Alcasabas et al, 2001).  Loss 
of Ada3 in MEFs was associated with markedly reduced acetylation of core histones and 
levels of p300 and PCAF (Mohibi et al, 2012). Another study using RNAi knockdown 
showed the role of Ada3 in G2/M progression (Orpinell et al, 2010). Together, these 
studies demonstrate an essential role of Ada3 in cell cycle progression in MEFs and in 
tumor cell lines (Kumar et al, 2002; Nag et al, 2007; Zeng et al, 2002; Meng et al, 2004; 
Germaniuk-Kurowska et al, 2007; Mohibi et al, 2012; Mirza et al, 2012).                                                                                            
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Further studies from our laboratory examined the expression of ADA3 in over 900 breast 
cancer tissue specimens (Mirza et al, 2013)  with known clinicopathological parameters 
and survival data (Zhao et al, 2012).  We showed ADA3 was predominantly nuclear in 
ER+ breast cancers, confirming our previous studies that ADA3 functions as an ER 
coactivator (Meng et al, 2004; Germaniuk-Kurowska et al, 2007); whereas ADA3 
expression was both nuclear and cytoplasmic in ER- breast cancers and this expression 
pattern correlated with high ErbB2/EGFR status and predicted poor patient survival 
(Mirza et al, 2013).  
In this study, we first confirmed our previous studies in ADA3fl/fl MEFs in immortal 
hMECs where ADA3 deletion led to delayed cell cycle progression. Detailed analyses in 
this system revealed the same Ada3-c-myc-Skp2-p27 axis that controls G1 to S phase 
progression and partly contributes to cell cycle delay upon Ada3 deletion. Additionally, 
loss of Ada3 showed dramatic decrease in acetylation of H3K56 that is known to play an 
important role in cell cycle.  Next, we examined the consequence of ADA3 
overexpression in immortal hMECs as well as in ER+ breast cancer cell lines. ADA3 
overexpression in both immortal hMECs, as well as in cancer cell lines dramatically 
enhanced cellular proliferation. Cell cycle analyses of ADA3 transfectants showed 
increased cyclin B, c-myc and decreased p27 levels.   ADA3 overexpression led to 
increase in mRNA levels of early response genes c-fos, EGR1 and c-myc levels. 
Analysis of a large cohort of ER+ breast cancer tissue specimens showed a subset of 
ER+ tumors express higher levels of ADA3, c-myc, and Ki67.  Comparison of four 
groups (ADA3 high/c-myc high, ADA3 high/ c-myc low, ADA3 low/c-myc high and ADA3 
low/c-myc low) showed significant a difference in cancer molecular subtypes, tumor 
grade, Nottingham Prognostic Index, and tumor types.  Thus, ADA3 expression in ER+ 





2.2 MATERIALS & METHOD 
 
Cells and Media: 76NTERT and 81NTERT, two immortalized human mammary 
epithelial cell lines, were grown in DFCI-1 medium, as described earlier (Band et al, 
1990; Band & Sager 1989).  MCF-7 and ZR-75-1 cell lines were grown in alpha-MEM 
supplemented with 10% fetal calf serum.  For estradiol starvation and stimulation 
experiments, MCF-7 and ZR75-1 cell lines were deprived in phenol red-free MEMA 
media (ThermoFisher Scientific, Waltham, MA, USA) supplemented with 5% charcoal 
stripped fetal calf serum (Atlanta Biologicals, Flowery Branch, GA, USA) and stimulated 
with 1nM β-estradiol (Sigma, St. Louis, MO, USA) for synchronization experiments 
(Germaniuk-Kurowska et al, 2007). 
 
Antibodies: Generation of anti-hAda3 mouse monoclonal antiserum has been described 
previously (Mohibi et al., 2012).  Antibodies against cyclin D1, cyclin E, ERα, Hsc70, 
PARP, and β-actin were purchased from Santa Cruz Biotechnology (Dallas, TX); SV-40, 
p27 and Cyclin B1 from BD Biosciences (San Jose, CA); c-MYC from Abcam, Inc 
(Cambridge, MA); Ki-67 from Dako (Carpinteria, CA); GAPDH from Cell Signaling 
(Danvers, MA); and H3 and H3K56 antibodies from Millipore (Billerica, MA). 
 
IHC Analysis: Cut sections of paraffin embedded patient derived xenograft (PDX) ER+ 
tumors samples were processed for ADA3, ERα and Ki-67 IHC staining using the 
method as described previously (Mirza, et al, 2013).   
 
Generation of stable hADA3 shRNA knockdown cells and Ada3 overexpressing 
cells: The hAda3-specific RNAi sequence used in shRNA constructs is as follows: 
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GCAATCAGAACAAGCCCTT. The oligonucleotide was cloned into the pSUPER-Retro 
vector (OligoEngine, Seattle, WA). 76NTERT cells were infected with hAda3 RNAi 
retroviral supernatants as described previously (Germaniuk-Kurowska, et al., 2007). 
Virally transduced cells were selected in 0.5 μg/ml puromycin for 3 days, and expression 
of endogenous hAda3 was assessed in the whole cell lysate using Western blotting 
using anti-Ada3 monoclonal antibody generated in our laboratory (Mohibi et al., 2012). 
The overexpressing constructs were generated by cloning the oligonucleotides in the 
pMSCV-Retro vector. 76NTERT, 81NTERT, MCF7, and ZR75-1 cells were infected with 
hAda3 overexpression retroviral supernatants as described in the same manner as 
shRNA infection. Virally transduced cells were selected in 0.5 μg/ml puromycin for 3 
days, and expression of endogenous hAda3 was assessed in the whole cell lysate using 
Western blotting using anti-Ada3 monoclonal antibody generated in our laboratory 
(Mohibi et al., 2012). 
 
Proliferation assay and cell cycle analysis: To perform proliferation assays 76NTERT 
and 81NTERT cells were plated at different numbers in 6 well plates in triplicates [5.0 x 
104(for counting on day 3), 2.5 x 104 (for counting on day 5), 1.25 x 104 (for counting on 
day 7) and 0.625 x 104 (for counting on day 9] and counted at the indicated time points.  
For cell cycle analysis, two days after plating 2 X 105 cells in 100 mm culture dishes, 
cells were synchronized by replacing the complete medium (DFCI-1 medium) with D3 
media and incubating for 72 h. Synchronized cells were stimulated with complete 
medium (DFCI-1 medium) for various time points and harvested and stained with 
propidium iodide (PI) for FACS analysis. MCF7 or ZR75-1 cells were plated 2 x 104 cells 
per well in 6 well plates in triplicates and counted every two days.  For estrogen 
independent growth analysis MCF7 and ZR75-1 cells were deprived of estrogenic 
compounds in phenol free MEMA supplemented with 5% charcoal dextran stripped FBS 
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for 72rs, stimulated with 1nM β-estradiol, and counted every two days.  C-myc level 
analysis in MCF7 cells was performed by 72hrs of estrogen deprivation and stimulation 
with 1nM β-estradiol. 
 
RNA Extraction and Quantitative Real-time PCR: TRIzol reagent (ThermoFisher 
Scientific, Waltham, MA) was used to isolate total RNA from cells. 2 μg of total RNA was 
used for reverse transcriptase reaction using SuperScriptTM II reverse transcriptase 
(Invitrogen). Real-time PCR quantification was performed in triplicates using SYBR 
Green PCR master mix (Applied Biosystems) and the primers are c-fos F: 
GGGGCAAGGTGGAACAGTTATC, c-fos R: TAGTTGGTCTGTCTCCGCTTGG, EGR1 
F: ACCTGACCGCAGAGTCTTTTCC, EGR1 R: CAGGGAAAAGCGGCCAGTATAG, c-
Myc: TCAAGAGGCGAACACACAAC, c-Myc R: GGCCTTTTCATTGTTTTCCA, β-actin 
F: ATCGTCCACCGCAAATGCTTCTA, β-actin R: AGCCATGCCAATCTCATCTTGTT, 
pS2 F: CCGAGGCCCAGACAGAGA, pS2 R: ACAGCAGCCCTTATTTGCAC, PR F: 
CCATGTGGCAGATCCCACAGGAGTT, PR R: TGGAAATTCAACACTCAGTGCC. 
 Expression levels were normalized against β-actin RNA levels, and the results were 
calculated by the ΔΔCt method.   
 
Analysis of the p27 Protein Turnover: For analyzing p27 protein half-life in 
exponentially growing cells, cells were treated with 25 μg/ml of cycloheximide (Sigma, 
St. Louis, MO) and harvested at the indicated time points. Total cell extracts were 
prepared, and equivalent amounts were run on SDS-PAGE and analyzed by Western 
blotting. The intensity of p27 bands was quantified by densitometry, normalized to β-
actin using ImageJ software. Percentage of normalized intensities were calculated and 
then converted to log values at base 2 and plotted on Y axis against time of 




Nuclear and cytoplasmic fractionation: Nuclear and cytoplasmic fractionation was 
performed using a purchased kit (ThermoFisher Scientific, Waltham, MA).  In brief, cells 
were trypsinized, pelleted, and washed with 1X PBS.  The pellet was resuspended in 
cytoplasmic extraction buffer 1, vortexed, and incubated on ice prior to the addition of 
cytoplasmic extraction buffer 2.  The tube was spun in a microcentrifuge (~16000 x g) 
before removal of the supernatant (cytoplasmic fraction).  Nuclear extraction reagent 
was added and the tub vortexed periodically over the course of 40 minutes before 
centrifugation and supernatant removal.  Equivalent supernatant volumes were run on 
SDS-PAGE and analyzed by western blotting.  PARP and GAPDH antibodies were used 
to assess nuclear and cytoplasmic extract purities, respectively.  
 
Statistical analysis of ADA3 and c-Myc IHC expression: ADA3 immunohistochemical 
(IHC) expression status of ADA3 was determined as per our previous publication 
(nuclear expression =>1 % was considered positive) (Mirza et al, 2013).  In addition, the 
nuclear IHC expression of c-myc was divided into in negative/weak (myc low) and 
moderate/strong (myc high) groups, nuclear expression of ADA3 as published previously 
(Mirza et al, 2013; Green et al, 2016). Accordingly, ADA3 and c-myc co-expression 
phenotypes were defined as follows: ADA3 low/ c-myc low, ADA3 high/ c-myc low, 
ADA3 low/ c-myc high , and ADA3 high/ c-myc high. Associations of these combinatorial 
phenotypes with different clinicopathological, as well as molecular markers were 
performed.  The statistical analysis was performed using Statistical Package for Social 
Sciences SPSS version 21 for Windows (Chicago, IL, USA). A p value of less than 0.05 
(two-tailed) was considered significant. Cut-off values for the different biomarkers 
included in this study were chosen before statistical analysis. Standard cut-offs were 
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used for established prognostic factors and were the same as for previously published 
patient series (Rakha et al, 2009).   
 
Karyotypic analysis: 76NTERT vector or ADA3 overexpressing cells were processed 
for karyotyping as done previously by our laboratory (Mirza et al, 2012).  
 
Invasion and migration analysis: Cells were deprived of estrogen for 72 hrs in phenol 
red free MEMA media supplemented with 5% charcoal dextran stripped fetal calf serum.  
5.0x103 cells in 500μl of deprivation media were added to the Matrigel or migration 
insert.  Two hours later 700μl of medium containing 1nM β-estradiol was added to the 
well to serve as the chemoattractant.  Inserts were subsequently stained using the Hema 
3 kit from Fisher (Waltham, MA) and the cells counted.  Invasion and migration of ADA3 
cells were normalized with respect to vector controls. 
 
Microarray analyses: Microarray preparation was performed as mentioned previously 









ADA3 is a nuclear protein in immortal hMECs, ER+ breast cancer cell lines, and is 
overexpressed in some ER+ breast cancer patient derived xenografts (PDX).
 Previous work performed by our laboratory showed Ada3 ablation in mouse 
embryonic fibroblasts (MEFs) led to delay in cell cycle progression and that cytoplasmic 
ADA3 expression correlated with poor prognosis and poor survival of ER- breast cancers 
(Mohibi et al, 2012; Mirza et al, 2013).  In this study, we focused on nuclear function of 
ADA3 using normal hMECs, ER+ breast cancer cell lines and ER+ breast cancer 
patients’ derived tissues.   
We initially examined immortal hMECs and ER+ breast cancer cell lines for 
ADA3 expression and found that ADA3 is differentially expressed (Figure 1A).  Next, we 
performed immunofluorescence staining and subcellular fractionation and found that 
ADA3 is localized in the nucleus (Figure 1B, 1C).  We then examined two ER+ patient 
derived xenograft (PDX) tumors using immunohistochemistry to assess ADA3 
expression. PDX tumors were generated by Dr. Welm’s laboratory by transplanting a 
portion of a tumor obtained from a patient directly into an immunocompromised mouse 
(DeRose et al, 2011).    By using these PDX samples, we observed that the ER+ Sample 
3 expressed intermediate levels of ADA3, while Sample 11 expressed high levels of 
ADA3.  Based on the known function of ADA3 in proliferation in MEFs, we assessed if 
high ADA3 expression correlates with Ki67, a well-known marker of proliferation 
(Urruticoechea et al, 2005).  Notably, ADA3 high tumor expressed much higher levels of 





Figure 1.   ADA3 is expressed and shows nuclear localization in the nucleus of 












Figure 1.   ADA3 is expressed and shows nuclear localization in the nucleus of 
normal and cancer mammary cell lines. (A) Western blot analysis of ADA3 in 
immortal hMECs (76NTERT, MCF-10A) and ER+ breast cancer cell lines (MCF-7, T47D, 
ZR-75-1).  (B) ADA3 immunofluorescence staining in MCF-7 and 76NTERT cell lines, 
DAPI was used for nuclear staining.  (C) Nuclear and cytoplasmic fractions were 
prepared from normal mammary epithelial cell (76N), immortal mammary epithelial cells 
(76NTERT and MCF-10A), and ER+ breast cancer cell lines (MCF-7, ZR-75-1). Protein 
concentration was quantitated and equal amount of protein was separated on SDS-
PAGE gel and expression was assessed with anti-ADA3, PARP or GAPDH. PARP was 





Figure 2. High ADA3 expression in patient derived xenografts correlates with 







Figure 2:  High ADA3 expression in patient derived xenografts correlates with 
elevated Ki67.  Patient-derived xenografts were sectioned and stained with antibodies 






ADA3 knockdown in immortal hMECs delays cell cycle progression.   
 We previously reported that homozygous deletion of Ada3 in mice led to 
embryonic lethality (Mohibi et al, 2012). Furthermore, conditional deletion of Ada3 in 
Ada3 fl/fl mouse embryonic fibroblasts (MEFs) showed a defect in cell cycle progression, 
including delayed G1 to S transition, mitotic catastrophe, and defective cytokinesis 
(Mohibi et al, 2012).  
 However, no studies have been performed so far to demonstrate such a role of 
ADA3 in hMECs.  Therefore, we first performed experiments to assess if ADA3 regulates 
cell cycle progression in hMECs.  For this purpose, we used control (scrambled) or a 
well characterized specific ADA3 shRNA (Nag et al, 2007) to knockdown Ada3 in the 
immortal hMEC cell line, 76NTERT.  Next, we synchronized 76NTERT cells by growth 
factor deprivation for 72 hours (0 time point), released the synchrony by adding medium 
containing growth factors, and then followed cell cycle progression over various 
indicated time periods. FACS-based cell cycle analysis of propidium iodide-stained cells 
showed significant delay in G1 to S progression in Ada3-deleted 76NTERT cells, as 
compared to control (Figure 3A). Of note, the relative distribution of S phase in Ada3-
knockdown hMECs after 16 h of growth factor stimulation was much lower (46 %) as 
compared to control  (64 %) (Figure 3A).  These results demonstrate that knockdown of 
Ada3 leads to delay in G1 to S progression in immortal hMECs, indicating essential role 
of ADA3 in efficient G1/S progression in hMECs, similar to our previous results in Ada3fl/fl 
MEFs upon cre-mediated deletion (Mohibi et al, 2012).  Knockdown of ADA3 was 
confirmed by western blotting (Figure 3 B, C).   
  Next, to examine if ADA3 plays a role in cell cycle progression, Ada3 knockdown or 
control 76NTERT cells synchronized and released from synchrony as above, were 
29 
 
analyzed for the levels of cell cycle proteins using western blotting.  Notably, significant 
alterations in the levels of cyclin B and E, and an increase in cyclin-dependent kinase 
inhibitor (CDKI) p27 levels during cell cycle progression were observed in Ada3 shRNA 
expressing immortal hMECs (Figure 3B).   
In consistent with our previous findings, western blotting using antibodies against 
histone H3 and H3-K56,  a significant reduction in acetylation of H3-K56 was observed 
upon Ada3 knockdown as compared to control (Figure 3C ), indicating that ADA3 is 
essential in maintaining histone acetylation during cell cycle progression. Taken 




Figure 3. Knockdown of ADA3 causes a delay in cell cycle progression in 
immortal hMECs. 
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Figure 3. Knockdown of ADA3 causes a delay in cell cycle progression in 
immortal hMECs. 
76NTERT cells expressing scrambled shRNA or Ada3 shRNA were deprived of growth 
factors in DFCI-3 media for 72hrs, then released from synchrony by adding growth factor 
containing DFCI-1 medium. Cells were then collected at the indicated time points for 
various analyses. (A) 76NTERT cells expressing scrambled shRNA or Ada3 shRNA 
were processed for FACS analysis after propidium iodide staining. Cell cycle profile 
(G1/S/G2/M) at selected time points is shown (B) Lysates were immunoblotted with 
indicated antibodies. β-actin was used as a loading control. (C)  Western blotting with 






Exogenous overexpression of ADA3 in immortal hMECs enhances proliferation 
and alters cell cycle regulatory proteins. 
  Human ADA3 was originally identified in our laboratory as a human papilloma 
virus (HPV) type 16 E6 interacting protein (Kumar et al, 2002) and by others’ as a p53 
stabilizing protein (Wang et al, 2001).  Initial studies by us and others showed that 
HPV16 E6 targeted ADA3 for degradation (Kumar et al, 2002; Shamanin et al, 2008), 
suggesting a tumor suppressor function of ADA3.  Furthermore, we reported that ADA3 
expression in normal mammary tissues and in ER+ breast cancer tissue is nuclear but 
ADA3 expression is cytoplasmic in ER- breast cancers (Mirza et al, 2013).  In ER- breast 
cancers, cytoplasmic expression of ADA3 correlated with poor prognosis and poor 
survival of patients. Based on these published results, and our results shown in Figure 2 
where ADA3 overexpression in ER+ breast cancer PDX correlated with high Ki67, we 
wished to assess if overexpression of nuclear ADA3 in immortal hMECs or in ER+ breast 
cancer cells have any consequence on proliferation. 
  For this purpose, we overexpressed ADA3 in two immortal hMECs 76NTERT 
and 81NTERT and then confirmed ADA3 overexpression using western blotting (Figure 
4A).  We then performed proliferation experiments by plating equal numbers of vector or 
ADA3 transfectants on day 0 and then every other day counted cells using a 
hemocytometer and trypan blue exclusion. Notably, ADA3-overexpressing immortal 
hMECs exhibited a significantly higher rate of proliferation as compared to control cells 
(Figure 4B, C). Notably, these cell lines despite of ADA3 overexpression, do not exhibit 
any chromosomal rearrangements, as seen by karyotype analyses (Figure 4G, E).  
Vector cells exhibit 19 breaks per 50 diploid metaphases scored, while ADA3 
transfectants exhibited 16 breaks per 50 metaphases scored.   Next, we analyzed 
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cell cycle regulatory proteins in vector or ADA3 overexpressing transfectants upon 
synchronization and then release from synchrony, as described above in Figure 3.  
Western blotting of lysates at various time periods during cell cycle progression showed 
clear alterations in the levels and timings of appearance of peak levels of cyclin B 
protein.  Significantly, in contrast to knockdown results, levels of p27 protein was 
dramatically decreased on cell cycle progression, indicating that decreased levels of p27 
may account for hyperproliferation of these cells (Figure 4D). Based on our previous 
findings in MEFs where knockdown of ADA3 significantly enhanced p27 half-life (Mohibi 
et al, 2012), we performed half-life experiments of p27 in vector or ADA3 overexpressing 
hMECs.  Transfectants were treated with cycloheximide to block new protein synthesis 
(0 time point) and then lysates were western blotted at various time points to assess p27 
levels.  Densitometric quantitation analyses showed turnover of p27 in ADA3 
overexpressing cells was much faster than in vector transfectants. Treatment of ADA3 
overexpressing cells with the ubiquitin proteasome inhibitor MG132, showed an increase 
in the level of p27 protein (compare 3 hour lane with or without MG132) (Figure 4E, F) 
confirming p27 turnover is proteasome-ubiquitin pathway dependent.  Analysis of mRNA 
levels of p27 showed no change (data not shown).  Taken together, our published data 
and results described here show p27 as an important mediator of ADA3 regulated cell 
proliferation in hMECs.  
  Consistent with our previous publication of ADA3 regulating c-myc-skp2-p27, we 
also analyzed c-myc levels in these experiments and observed a significant increase in 
c-myc levels in ADA3 overexpressing cells, underscoring a positive connection of ADA3 




























Figure 4.  Exogenous overexpression of ADA3 leads to increased proliferation.   
(A) Western blotting of cells overexpressing ADA3.  76NTERT cell line (B) or 81NTERT 
cell line (C) expressing an empty vector or ADA3 were plated at a density of 1 x 104 and 
then counted using a hemocytometer on alternate days to measure proliferation. (D) 
western blotting of cell lysates from synchronized (0 time point) or cells released from 
synchrony (1-28 hours) were immunoblotted with indicated antibodies. β-actin was used 
as a loading control.  (E) p27 half-life analysis. 76NTERT cells overexpressing ADA3 
were treated with cycloheximide, cells lysates at indicated time points were 
immunoblotted with anti-p27 antibody. Last lane 3 hour time point of cells treated with 
MG132  (F) The intensity of p27 bands was quantified by densitometry, normalized to β-
actin using ImageJ software, and plotted against the time of cycloheximide treatment. .  
G) Representative karyotype of 76NTERT vector cells and E) Representative karyotype 





Exogenous overexpression of ADA3 in immortal hMECs enhances transcription of 
early response genes.  
 Given the change in c-myc protein levels and previous findings that ADA3 as part 
of STAGA complex enhances c-myc transcription; we analyzed transcription of c-myc 
along with two other early response genes c-fos and EGR1.  For this purpose, vector or 
ADA3-overexpressing transfectants were growth factor deprived for 72 hrs, and then 
released from synchrony via the addition of growth factor containing media, followed by 
analyses of mRNA levels of early response genes by quantitative-PCR (qPCR) analysis 
at different time points.  Significantly, in each case mRNA levels of early response 
genes, c-fos, EGR1 and c-Myc peaked at 1 hour in both vector and ADA3 transfectants; 
however levels were much higher in ADA3 transfectants as compared to vector alone. 
Significantly, the levels of all three early response genes remained higher in ADA3 
transfectants in all time points analyzed (Figure 5). These results suggest myc and early 












Figure 5.  ADA3 transcriptionally regulate early response genes.   76NTERT cells 
vector or ADA3 overexpressing were deprived of growth factors for 72 hours and then 
released from synchrony via growth factor stimulation. Cells were collected at the 
indicated time points and total RNA was extracted for real time PCR analyses. Real time 







Exogenous overexpression of ADA3 in ER+ breast cancer cell lines enhances 
proliferation.  
  Given the role of ADA3 in cell proliferation in hMECs, its overexpression seen in 
PDX models of ER+ breast cancers, and ADA3 connection with c-myc transcription, we 
assessed if ADA3 overexpression in ER+ breast cancer cells also influences cell 
proliferation.  For this purpose, we selected two well studied ER+ breast cancer cell lines 
MCF-7 and ZR-75-1, both of these express similar levels of nuclear ADA3 as seen in 
immortal hMECs.  Overexpression was confirmed using western blotting (Figure 6A).  
Significantly, similar to ADA3 overexpression in immortal hMECs, overexpression of 
ADA3 in both ER+ breast cancer cell lines led to hyperproliferation (Figure 6B, C).  Next, 
we examined if ADA3 overexpression induced estrogen independence for proliferation in 
these cell lines.  For this purpose proliferation of both transfectants were analyzed under 
both estrogen deprivation and estrogen presence.  These analyses showed ADA3 
overexpression does not alter estrogen dependence of these cells (Figure 7A, B).  
Taken together, our results demonstrate that ADA3 overexpression induces 




Figure 6. Exogenous overexpression of ADA3 leads to increased proliferation of 











Figure 6.  Exogenous overexpression of ADA3 leads to increased proliferation of 
ER+ breast cancer cell lines. (A) Western blotting of cell lysates from MCF7 and ZR-
75-1 expressing vector or ADA3. MCF-7(B) or ZR-75-1 (C) cell lines expressing an 
empty vector or ADA3 were plated at a density of 1.0x104 cells and counted on alternate 


















Figure 7. ADA3 overexpression does not induce estrogen independence for 
proliferation. Indicated cell lines overexpressing  vector (V) or ADA3 were 
deprived of estrogen in phenol red-free MEMA medium supplemented with 5% 
charcoal dextran stripped fetal calf serum for 72hrs and stimulated with 1nM of β-
estradiol.  Fresh medium was added on alternate days and total number of cells 





ADA3 overexpression in immortal hMECs or ER+ breast cancer cell lines does not 
alter invasion or migration properties of cells. 
  While hyperproliferation is shown to be an important step in tumor formation, 
there is ample evidence that hyperproliferation does not always correlate with invasion 
or migration of tumor cells (Khoshyomn et al, 1999).  Given that ADA3 overexpression 
led to hyperproliferation, we assessed f hyperproliferation provides these cells ability to 
better invade or migrate.  For this purpose standard invasion and migration assays were 
performed.  As shown in Figure 8 (A and B) no significant differences were observed in 
vector and ADA3 overexpressing ZR-75-1 cells.  These results clearly demonstrate the 




Figure 8.  ADA3 overexpression has no effect on invasion or migration of cells.  
 







Figure 8.  ADA3 overexpression has no effect on invasion or migration of cells.    
ZR-75-1 , an ER+ breast cancer cell line expressing vector (V) or ADA3 was 
examined for changes in invasive (A) or migratory (B) potential using the Boyden 





ADA3 is overexpressed in a subset of ER+ breast cancers, and its overexpression 
positively correlates with expression of c-myc.    
 Given the vast body of literature supporting a role of c-myc in breast cancers (Xu 
et al, 2010; Dang, 2012), amplification of c-myc is seen in approximately 15% of breast 
cancers (Xu et al, 2010), and its overexpression is associated with poor outcome (Xu et 
al, 2010; Wolfer et al, 2010; Huang, et al 2014). Our collaborators analyzed a large 
cohort of breast cancer specimens containing various subtypes and observed that c-myc 
overexpression was significantly associated with poor prognostic factors, including grade 
and basal-like breast cancers (Green et al, 2016). C-myc was also observed to be an 
independent predictor of a shorter distant metastases-free survival in luminal A 
LN+ tumors treated with endocrine therapy (Green et al, 2016).  These patients’ tissue 
specimens were also analyzed for ADA3 protein in our previous study (Mirza et al, 
2013).  In this study, we used this set of tissue specimens to access if ADA3 and c-myc 
expression correlated in these tissue specimens.  
There were 598 ER+ patient samples where ADA3 expression was examined by 
IHC; and 796 samples had c-myc data.  When combined these two markers, there were 
429 patient samples suitable for comparative analysis of ADA3 and c-myc levels.  Of 
these samples, 172 had low levels of both ADA3 and c-myc, 178 were low for ADA3 and 
high for c-Myc, 69 were high for ADA3 and low for c-myc, and 169 were high for both 
(Table 1).  Notably, these analyses showed a highly significant difference (p <0.0001) 
among ADA3 high/c-myc high, ADA3 high/ c-myc low, ADA3 low/c-myc high and ADA3 




Table 1. Significant association between Positive Nuclear expressions of ADA3 
and c-myc in unselected breast cancer cases. 
 
Using tissues from the breast cancer specimen cohort we analysed only ER+ samples 
for high and low ADA3 and c-myc expression.  We found that among the four groups 
there is a statistically significant difference.  
 
Parameter 









Negative/Low  172 (49.1) 178 (50.9)  
23.79 
 





 Next, we compared these four group ADA3 high/c-myc high, ADA3 high/ c-myc 
low, ADA3 low/c-myc high and ADA3 low/c-myc low in ER+ and ER- patient samples for 
phenotypic groups / molecular biomarkers’ status and clinical-pathological parameters 
and found that these 4 groups showed significant difference in tumor grade, Nottingham 
Prognostic Index and tumor types (Table 2) and cancer molecular subtypes, Ki67, as 
well as p27 (Table 3).  Lastly, when we analyzed nuclear co-expression of ADA3 and c-
myc with molecular biomarker status within only ER+ tumors we observed statistically 
significant correlations in tumor grade, nuclear pleomorphism, Nottingham Prognostic 
Index, Lymphovascular Invasion, histological tumor type, Ki67, and p27 across the four 
groups (Table 4).  
Taken together, these results show i) ADA3 overexpression is seen in a subset 
of ER+ patients ii) ADA3 overexpression correlates with c-myc overexpression and iii) 
ER+ breast cancers can be categorized into 4 groups ADA3 high/c-myc high, ADA3 
high/ c-myc low, ADA3 low/c-myc high and ADA3 low/c-myc low iv) these four 
subgroups show significant differences in their association with biomarkers, particularly 
c-myc and p27 expression, grades of tumors.  Future study will be extended to compare 




Table 2. Relationship between nuclear ADA3 and nuclear c-myc co-expression 
groups and clinic-pathological parameters.   
 
 
Analysis of all patient specimens from all members of the unselected invasive breast 
cancer cohort demonstrates a significant correlation between nuclear ADA3 and c-myc 
levels in the areas of tumor grade, pleomorphism, tubule formation, mitotic scores, NPI, 
and tumor type across the four groups. 
  
Parameters 































≤ 50 66 (31.7) 24 (11.5) 65 (31.1) 53 (25.5) 1.862 0.602 




Pre 66 (30.4) 25 (11.5) 68 (31.3) 58 (26.7) 0.907 0.871 
Post 106 (28.6) 44 (11.9) 110 (29.7) 110 (29.7) 
Tumour 
size 
≤ 2 cm 96 (28.0) 14 (12.0) 99 (28.9) 107 (31.2) 2.765 0.429 
>2 cm 76 (31.4) 28 (11.6) 77 (31.8) 61 (25.2) 
Tumour 
grade 




2 47 (25.3) 18 (9.7) 48 (25.8) 73 (39.2) 
3 105 (33.3) 37 (11.7) 112 (35.4) 62 (19.6) 
    
Tubules 




2 47 (25.1) 21 (11.2) 59 (31.6) 60 (32.1) 
3 116 (32.7) 35 (9.9) 107 (30.1) 97 (27.3) 
    
Pleomo
rphism 




2 57 (26.0) 31 (14.2) 46 (21.0) 85 (38.8) 
3 110 (32.6) 31 (9.2) 122 (36.2) 74 (22.0) 
    
Mitosis 




2 30 (29.1) 9 (8.7) 30 (29.1) 34 (33.0) 








2 57 (28.2) 23 (11.4)  68 (33.7) 54 (26.7) 
3 22 (37.3) 4 (6.8)  20 (33.9) 13 (22.0) 
NPI 




Moderate 103 (33.0) 40 (12.8) 88 (8.8) 81 (28.2) 






Negative  106 (28.0) 52 (13.8) 103 (27.2) 117 (31.0) 10.624
 
0.014 
Positive 64 (31.4) 16 (7.8) 75 (36.8) 49 (24.0) 
Tumour 
type 





Invasive Lobular 13 (22.4) 8 (13.8) 4 (6.9) 33 (56.9) 





5 (25.0) 6 (30.0) 5 (25.0) 4 (20.0) 
Tubular Mixed
 
20 (20.6) 11 (11.3) 28 (28.9) 38 (39.2) 
Mixed NST & 
Lobular 
4 (19.0) 2 (9.5) 6 (28.6) 9 (42.9) 
Mixed NST &other 
special types 
2 (25.0) 0  3 (37.5) 3 (37.5) 
N= number of cases. c. = cytoplasmic, n. = nuclear expression. NST= No Special Type. NPI= Nottingham 
Prognostic Index.
 * 




Table 3.   Relationship between nuclear ADA3 and nuclear c-myc co-expression 



































































































High 83 (29.9) 30 (10.8) 101 
(36.3) 
64 (23.0) 
p27 Low 114 
(38.8) 




High 40 (16.7) 33 (13.8) 77(32.1) 90 (37.5) 
*HER2 Status was assessed using American Society of Clinical Oncology/College of American 
Pathologists Guidelines Recommendations for HER2 Testing in Breast Cancer and Equivocal 
(2+) HER2+ cases were confirmed by FISH/CISH.  ** Ki67 labelling index dichotomised at 
14% according to St Galen consensus guidelines 2013.    
 
 
Analysis within the whole unselected invasive breast cancer series of all patient 
specimens with respect to receptor status, molecular subtype, Ki67 labeling index, and 
p27 demonstrated a statistically significant correlation across the four groups. 
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Table 4.   Relationship between nuclear ADA3 and nuclear c-myc co-expression 
groups with molecular biomarker status within ER+ tumors only.   
 
 
Analysis of ER+ patient specimens with respect to tumor grade, nuclear pleomorphism, 
NPI, LVI, histologic tumor type, Ki67 labeling index, and P27 demonstrated a statistically 
significant correlation across the four groups. 
Parameters 





























Patient age  ≤ 50 35 (26.3) 18 (13.5) 39 (29.3) 41(30.8) 0.469 0.936 
> 50 78 (26.0) 38 (12.7) 82 (27.3) 102 (34.0) 
Menopausal 
Status 
Pre 35 (24.5) 19(13.3) 44 (30.8) 45 (31.5) 1.002 0.801
1 
Post 78 (26.9) 37 (12.8) 77 (26.6) 98 (33.8) 
Tumour size ≤ 2 cm 65 (24.3) 34 (12.7) 74 (27.6) 95 (35.4) 1.968 0.579 
>2 cm 48(29.3) 22 (13.4) 45 (27.4) 49 (29.9) 
Tumour 
grade 




2 44 (25.6) 16 (9.3) 44 (25.6) 68 (39.5) 
3 51 (28.5) 26 (14.5) 59 (33.0) 43 (24.0) 
    Tubules 




2 41 (25.2) 17 (10.4) 51 (31.3) 54 (33.1) 
3 65 (28.1) 27 (11.7) 60 (26.0) 79 (34.2) 
    
Pleomorphis
m 




2 52 (24.9) 31 (14.8) 42 (20.1) 84 (40.2) 
3 58 (29.1) 19 (9.5) 71 (35.7) 51 (25.6) 
    Mitosis 




2 23 (25.3) 8 (8.8) 30 (33.0) 30 (33.0) 
3 48 (30.4) 21 (13.3) 48 (30.4) 41 (25.9) 
Axillary 
nodal stage 




2 43 (26.7 17 (10.6) 50 (31.1) 51 (31.7) 
3 12 (32.4) 4 (10.8)  10 (27.0) 11 (29.7) 
NPI 




Moderate 63 (29.3) 31(14.4) 56(26.0) 65(30.2) 

















Invasive Lobular 13 (22.4) 8 (13.8) 4 (6.9) 33 (56.9) 





5 (26.3) 6 (31.6) 5 (26.3) 3 (15.8) 
Tubular Mixed
 
16 (17.4) 11 (12.0) 28 (30.4) 37 (40.2) 
Mixed NST & 
Lobul r 








Low 35 (23.0) 25 (14.8) 33 (21.9) 68 (40.4) 11.217
  
0.011 
High 49 (29.9) 22 (10.8) 38 (36.3) 50 (23.0) 
p27  Low 61 (35.5) 21 (12.2) 47 (27.3) 43 (25.0) 18.993
 <0.00
1 
High 37 (16.9) 32 (14.6) 67 (30.6) 83 (37.9) 
N= number of cases. c. = cytoplasmic, n. = nuclear expression. NST= No Special Type. NPI= Nottingham 
Prognostic Index.
 * 





 Precisely regulated cell cycle progression is essential for embryonic development 
as well as in adult tissue homeostasis (Kastan & Bartek, 2004). Coordination of cell 
cycle progression with chromosomal duplication maintains genomic stability; a critical 
cancer-associated trait (Schvartzman et al, 2010).   Deregulated cell cycle components 
have emerged as key biomarkers and therapeutic targets in cancer (Lapenna & 
Giordano, 2009). Thus, a better understanding of cell cycle machinery and its 
aberrations in cancer are of fundamental importance in cell and cancer biology.   
 We previously identified the ADA complex component ADA3 as an HPV 16 E6 
oncoprotein partner as well as a coactivator of cell cycle checkpoint regulator and tumor 
suppressor p53 (Kumar et al, 2002; Nag et al, 2007).  We and others have shown that 
ADA3 is a target for E6-mediated degradation, suggesting its tumor suppressor function. 
Several studies have shown that ADA3 is an essentially universal component of a 
multitude of HAT-based transcriptional regulatory complexes.  We previously 
demonstrated that ADA3 interacts with steroid hormone receptors retinoic acid (Zeng et 
al, 2002), and estrogen receptors (ER) (Meng et al, 2004; Germaniuk et al, 2007) and 
functions as a coactivator to enhance their transactivation and function. We also showed 
that in breast cancer cells ADA3 is in a large complex that include components of the 
yeast Ada complex (Ada2, Ada3 and GCN5, a HAT) but also other cell cycle- and 
cancer-associated HATs, p300 and PCAF (Germaniuk et al, 2007).  Further analyses 
from our laboratory demonstrated Ada3 deletion in mice is embryonic lethal and knock 
out from Ada3fl/fl MEFs led to cell cycle delay.  Our previous analyses of a large cohorts 
of breast cancer tissue specimens, showed while ADA3 is a nuclear protein in normal 
mammary cells, as well as in ER+ breast cancer cells, it is localized to cytoplasm in ER- 




In this study, we focused our analyses to mammary epithelial cells, which are the 
precursors of most breast carcinomas and explored the role of ADA3 in human 
mammary epithelial cells and in ER+ breast cancers.  Using immortal (non-tumorigenic) 
hMEC lines and ADA3 shRNA-mediated knockdown and overexpression, we 
established a clear role of ADA3 in breast cells.  We demonstrated that knockdown of 
ADA3 in immortal hMECs led to delay in cell cycle progression as seen by accumulation 
of cells in G1 to S transition. As cell cycle progression is a tightly regulated process and 
is dependent on sequential and stringently controlled, concerted activation of Cdks and 
their inhibition by Cdk inhibitors, we analyzed effect of ADA3 knockdown in mammary 
cells. We observed dramatic changes in regulation of Cyclin E and B, as well as 
upregulation of p27 protein, consistent with our previous findings in MEFs. In addition, 
we observed a dramatic decrease in H3K56 protein in immoral hMECs.  These results 
are consistent with a vast body of literature suggesting highly significant role of H3-K56 
acetylation in DNA replication and cell cycle (Wurtele et al, 2012; Li et al, 2008; Yu et al, 
2012). These results, together with our previous published findings clearly demonstrated 
a role of ADA3 in hMECs cell cycle progression. 
 Given that several cell cycle regulatory proteins are upregulated in cancers to 
help maintain the higher proliferation demand of cancer cells, we analyzed patient 
derived xenograft tissue from two ER+ breast cancer patients.  Surprisingly, we 
observed in one tumor specimen ADA3 levels were substantially higher than other ER+ 
tissue specimen, suggesting that ADA3 expression may be different in various ER+ 
breast cancers.  Interestingly, high ADA3 expression in one sample also correlated with 
high K67 protein, a marker of cell proliferation.  These results prompted us to 




 While ADA3 knockdown/knockout significantly halts cell cycle progression, 
overexpression of ADA3 significantly induced hyperproliferation.  Importantly, 
hyperproliferation was associated with increased Cyclin B levels and downregulation of 
p27 protein due to rapid turnover. As our previous results showed ADA3 enhances c-
myc transcription (Mohibi et al, 2012), we assessed c-myc levels in these ADA3 
overexpressing cells and found that not only c-myc but also two other early response 
gene, c-fos and EGR1 were significantly high in ADA3 overexpressing cells.  C-fos has 
long been known to be involved in proliferation and EGR1 has also been found to be 
important for cell proliferation and migration (Angel & Karin, 1991; Mitchell et al, 2004; 
Min et al, 2008), therefore elevated expression levels of both in ADA3 overexpressing 
cells is consistent with their role in proliferation. These results are consistent with our 
previous findings where we defined ADA3-c-myc-skp2-p27 pathway for role of ADA3 in 
cell cycle regulation in MEFs. We and others have previously reported that Ada3 as part 
of STAGA complex binds to c-myc enhancer elements (Wang et al, 2001; Shamanin et 
al, 2008).  Notably, another ER coactivator, SRC3 has also been shown to enhance 
proliferation when it is overexpressed (Louie et al, 2004) suggesting role of ER 
coactivators in cellular proliferation.  However, we and others have not seen presence of 
SRC3 in ADA3 containing complexes, suggesting different mechanism of action of these 
two ER coactivators.   
 Finally, given a vast body of literature linking c-myc expression, as a key 
regulator of cell proliferation, metabolism, differentiation, and apoptosis and our results 
that ADA3 regulates c-myc levels, prompted us to analyze ER+ breast cancer 
specimens where c-myc is shown to be important for breast cancer development and 
progression and is associated with poor outcomes.  
Analyses of a well characterized cohort of breast cancer tissue samples, we report that 
ER+ tumors can be divided into high and low groups, based on ADA3 protein levels.  
58 
 
Notably, analyses showed a highly significant difference among four groups; ADA3 
high/c-myc high, ADA3 high/ c-myc low, ADA3 low/c-myc high and ADA3 low/c-myc low 
group of patients (Table 1). When combined both ER+ and ER- cases,  ADA3 high/c-
myc high, ADA3 high/ c-myc low, ADA3 low/c-myc high and ADA3 low/c-myc group of 
patients showed significant differences in their correlations with various biomarkers (p27 
and c-myc), cancer molecular subtypes, pleomorphism, mitosis, tumor grade, 
Nottingham Prognostic Index and tumor types.    
   
Conclusions 
 
We demonstrate that ADA3 is overexpressed in ER+ breast cancers, its overexpression 
induces c-myc induction and together expression of both ADA3 and c-myc proteins 
induced hyperproliferation of cells. ADA3 overexpression together with c-myc can divide 
patients into four groups with significant differences in phenotypic groups, and molecular 
biomarkers’ status and clinical-pathological parameters. 
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Other experiments performed during my Ph.D. studies 
 
In addition to the above studies that have been compiled into a manuscript, 
additional experiments were performed to determine ER target gene expression 
and tamoxifen sensitivity  in ER+ breast cancer cell lines.  Invasion and migration 
was measured in the 21PT and 21MT2 ErbB+ breast cancer cell lines.  Lastly, 
microarray analysis of asynchronous 76NTERT vector and ADA3 transfectants 
was performed to ascertain alterations in basal gene transcription.   
 
Ada3 overexpression leads to increased ER target gene expression 
  
  In order to determine if any ER target genes were affected by ADA3 
overexpression in MCF-7 cells, we deprived and stimulated cells as in Figure 5A, then 
collected triplicate samples of mRNA after 24hrs for real time PCR analysis.  After 
normalization with β-actin and untreated vector cells, we found that ADA3 
overexpressing cells expressed a greater amount of mRNA for pS2 and c-myc, two well-
known ER target genes.  However, there was no change in progesterone receptor 
levels, which could be attributed to experimental error (Figure 9).  These data are 
consistent with that ADA3 functions as a coactivator of ER and enhances the expression 









Figure 9.  Ada3 overexpression leads to increased ER target gene expression.   
Following 72hr deprivation and subsequent β-estradiol stimulation for 24hrs, MCF7 
cells overexpressing ADA3 have increased ER target gene expression levels as 






ADA3 overexpression does not alter tamoxifen sensitivity 
 To further examine the effect of ADA3 and consequently c-myc overexpression 
on ER+ breast cancer cell lines, we treated them with varying doses of 4-hydroxy-
tamoxifen (4-OHT), a well-known estrogen antagonist.  MCF-7 (Figure 10A) and ZR-75-
1 (Figure 10B) transfectants with vector or Ada3 were treated with the indicated doses of 
tamoxifen for seven days.  Following the course of treatment, live cells were counted 
using trypan blue exclusion dye and a hemocytometer.  As expected, at lower doses of 
tamoxifen, it functions as an estrogen agonist thus enhances proliferation (Smith et al., 
1997); however, there was no discernible cell survival difference between vector cells 
and cells overexpressing ADA3 at higher doses of tamoxifen.  Using the more sensitive 
cell titer glow approach, 1.0x104 ZR-75-1 vector or ADA3 overexpressing cells were 
treated with concentrations of 4-OHT as indicated in Figure 10 (C-F) for eight days in a 
96 well plate.  Fluorescence readings were taken every two days and normalized to the 
initial day of plating.  Again, no significant change in tamoxifen sensitivity was observed 
between vector and ADA3-overexpressing cells.  Thus, ADA3-induced overexpression of 















Figure 10. ADA3 overexpression does not alter tamoxifen sensitivity. 
 
   
 






Figure 10. Ada3 overexpression does not alter tamoxifen sensitivity. 
(A) MCF7 or (B) Zr75-1 cell lines overexpressing Ada3 were continuously treated with 4-
hydroxy-tamoxifen (4-OHT).  1.0x10^4 cells were treated with the indicated 
concentrations of 4-OHT and live cells counted after seven days using a 
hemocytometer.  (C-F) ZR75-1 cells overexpressing Ada3 were treated with 4-OHT and 
quantified using cell titer glow.  1.0x10^3 cells treated with the indicated concentrations 





ADA3 overexpression does not alter tumorigenic phenotypes, invasion and 
migration in ErbB2+ cell lines.  
In addition to proliferation, two other processes known to be altered in cancers are 
invasion and migration.  Invasion is the ability of a cell to pass through the extracellular 
matrix by cleaving proteins in the way, while migration is when the cell moves by 
rearranging the cytoskeleton or membrane.  Matrigel serves as medium through which 
cells invade, while migration occurs across a porous membrane.  In addition to the two 
ER+ breast cancer cell lines (MCF-7 and ZR-75-1) we examined in Chapter 2, we took 
two ErbB2+ (21PT and 21MT2) ADA3 overexpressing transfectants and  examined their 
abilities to invade and migrate.  Following the conclusion of the invasion and migration 
time points, cells were stained, photographed, and counted with ImageJ software.  The 
average values of 4 Ada3 overexpressing inserts were normalized to that of vector 
inserts.  21PT and 21MT2 cells were plated in serum free MEMA, while the lower 
chamber was supplemented with 10% serum as a chemo-attractant.  21PT cells 
underwent both invasion and migration after 24hrs (Figure 11A and 11B), while the 
21MT2 cells invaded after 72hrs (Figure 11C) and migrated after 40hrs (Figure 11D).  





Figure 11.  Ada3 overexpression has no effect on invasion and migration in 
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Figure 11.  Ada3 overexpression has no effect on invasion and migration.    
ErbB2+ breast cancer cell lines were examined for changes in invasive and migratory 
potential.  21MT2 (A) and (B) cell lines overexpressing Ada3 were assessed using 10% 
FBS as the chemoattractant. Invasion and migration were normalized with respect to 





Overexpression of Ada3 leads to global gene expression changes 
 Due to the observed increased in proliferative capability, we performed 
microarray analysis on 76NTERT vector control cells and Ada3 overexpressing cells.  As 
anticipated, the expression levels of many genes were changed. 582 genes were 
upregulated and 587 genes were downregulated ≥1.2 fold upon the overexpression of 
Ada3 in 76NTERT cells.  This differential expression is similar to previous work 
performed in our lab by Mohibi, et al. in 2012.  Analysis of the array done using Ingenuity 
Pathway Analysis showed that the primary biological functions most affected by Ada3 
overexpression were related to the cell cycle (379 genes) and DNA replication, 
recombination, and repair (309 genes) (Table 5).  Of note, few of the primary altered 
biological functions are shared with the observations obtained when Ada3 was deleted 
(Mohibi et al, 2012).  When further examining the well mapped out canonical pathways 
in IPA, we found that the top affected pathways followed the general trend of being 




Table 5.  Top biological functions affected in overexpressing Ada3 cells as 
obtained from Ingenuity Pathway Analysis 
Name p-value # Molecules 
Diseases and Disorders 
Cancer 3.19E-46 - 5.12E-03 2072 
Gastrointestinal Disease 4.98E-30 - 3.55E-03 1469 
Organismal Injury and 
Abnormalities 
6.56E-19 - 5.26E-03 982 
Reproductive System 
Disease 
6.56E-19 - 5.24E-03 870 
Hepatic System Disease 7.77E-12 - 3.55E-03 876 
Molecular and Cellular Functions 
Cell Cycle 4.20E-23 - 5.12E-03 379 
Cellular Assembly and 
Organization 




4.20E-23 - 5.26E-03 309 
Nucleic Acid Metabolism 7.81E-10 - 2.17E-03 141 
Small Molecule 
Biochemistry 
7.81E-10 - 5.11E-03 164 
Physiological System Development and Function 
Embryonic Development 5.82E-07 - 3.43E-03 199 
Organismal Survival 5.82E-07 - 5.82E-07 42 
Reproductive System 
Development and Function 
1.14E-05 - 5.22E-03 119 
Connective Tissue 
Development and Function 
2.02E-05 - 4.61E-03 39 
Organ Morphology 3.22E-05 - 5.22E-03 73 
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Table 6: Top canonical pathways affected in overexpressing Ada3 cells as 
obtained from Ingenuity Pathway Analysis 
 
Name p-value Ratio 
Cell Cycle: G2/M DNA 
Damage Checkpoint 
Regulation 
1.41E-12 26/49 (0.531) 
Role of BRCA1 in DNA 
Damage Response 
4.59E-10 27/64 (0.422) 
Mitotic Roles of Polo-Like 
Kinase 
5.59E-09 26/66 (0.394) 
ATM Signaling 2.6E-07 22/59 (0.373) 
Cell Cycle Control of 
Chromosomal Replication 














 Interestingly, the top affected network controls cell death and survival, amino acid 
metabolism, and post-translational modification (Figure 12A), while the second most 
affected network influences cellular assembly and organization, cellular function and 
maintenance, and the cell cycle (Figure 12B).  The top five differentially regulated 
networks are compiled in Figure 12 (A-E).  The dysregulated networks are similar when 
Ada3 is overexpressed in that cell cycle related networks and developmental networks 
are altered, however the changes are not an exact match. 
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Figure 12. Network 2: Cellular assembly and organization, cellular 





Figure 12. Network 3: Cell-to-cell signaling and interaction, 





Figure 12. Network 4: Metabolic disease, amino acid metabolism, 







Figure 12. Network 5: Dermatological diseases and conditions, 





Figure 12. Top 5 cellular networks affected by Ada3 overexpression as obtained 
from Ingenuity Pathway Analysis.  (A-E) The top 5 networks affected upon Ada3 
overexpression as obtained from Ingenuity Pathway Analysis.  All the genes up or down 











GENERATION OF AN ADA3FL/FL, GFP, CRE-ERT2 MOUSE MODEL 






 The majority of mammary gland development occurs postnatally after puberty, 
making it a unique organ system (Macias & Hinck, 2012).  In mice, rudimentary ducts 
are present at birth, which grow into the surrounding tissue post puberty.  The ducts give 
rise to the ductal tree consisting of mammary epithelial cells and the surrounding tissue 
composed of adipocytes form the stroma containing the mammary fat pad.  Together 
these make up the two primary parts of the mammary gland.  During pregnancy and 
subsequent involution the epithelial cells of the ductal tree go through multiple cycles of 
increased proliferation followed by apoptosis (Macias & Hinck, 2012).  The initial 
proliferation is stimulated by hormonal changes, leading to the formation of alveolar 
structures within the ducts that lactate.  After lactations ends, the apoptosis begins 
leading to involution and a return of the gland to the pre-pregnancy state (Macias & 
Hinck, 2012).   
 Estrogen receptors are well known as being critical to the development of the 
mammary gland (Bocchinfuso & Korach, 1997).  Previous work from our laboratory 
found that Ada3 is an important co-activator for the estrogen receptor (Meng, et al, 2004; 
Germaniuk-Kurowska et al, 2007).  Additionally, it was found that Ada3 regulates c-myc 
transcription and deletion leads to block in cell cycle progression (Mohibi et al, 2012).   
Our recent work showed that Ada3 is overexpressed in ER+ breast cancers and its 
overexpression induces an increase in proliferation and consequently increase in c-myc 
levels through the same c-myc-Skp2-p27 mediated pathway as we observed in MEFs 
(Griffin et al, submitted).  Thus, in order to examine the effects of Ada3 on the 






3.2 MATERIALS & METHODS 
 
Mice, genotyping, and DNA isolation 
 The generation of mice containing floxed ADA3 genes (ADA3FL/FL) with a GFP 
reporter has been previously described (Mohibi, et al., 2012).  FVB background Cre-
ERT2 tamoxifen inducible transgenic mice were ordered from the Jackson Laboratory to 
maintain the FVB/N background.  Genotyping occurred at 2-3 weeks of age when pups 
were tattooed and a tail piece trimmed for DNA isolation using a Qiagen kit (Valencia, 
CA).  Proteinase K was added to the cell lysis solution and tail pieces were digested 




 The harem mating strategy was used to generate all mice used in this study, with 
pups being weaned at 21days of age.  Vaginal plugs were monitored to track timed 
pregnancies.  Cre-ERT2 breeding was set so only one parent possessed the Cre gene 
as per the recommendation of the Jackson Laboratory, as two copies of Cre result in 
lethality.   
 
Cell line generation 
 Breeding was set to ensure parental mice were both ADA3FL/+ and GFP+, while 
only the mother was Cre-ERT2+.  13.5 days following verification of a vaginal plug, the 
embryos were isolated and immortalized following the 3T3 protocol (Todaro & Green, 
1963) using Dulbecco’s modified Eagle medium supplemented with 10% fetal bovine 
serum.  Verification of Cre-ERT2 mediated deletion was performed by treating cell lines 
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genotyped as ADA3FL/FL, GFP+, Cre-ERT2+ or ADA3FL/+, GFP+, Cre-ERT2+ with 1μM of 
tamoxifen (4-OHT) for 72hrs, with media changes occurring daily. 
 
Antibodies: Generation of anti-hAda3 mouse monoclonal antiserum has been 
described previously (Mohibi et al., 2012).  β-actin and GFP antibodies were purchased 
from Santa Cruz.   
 
3.3 RESULTS 
Generation of Cre-ERT2 conditional deletion MEF cell lines 
 After the isolation of embryos to generate inducible deletion cell lines, DNA was 
isolated and genotype using the methods and primers described previously in Mohibi, et 
al, 2012.  A total of ten embryos were analyzed.  Embryos 3, 7, and 9 exhibited the 
desired ADA3FL/FL, GFP+, Cre-ERT2 genotype, while embryos 2, 4, 5, and 10 exhibited 
the desired control ADA3FL/+, GFP+, Cre-ERT2 genotype (Figure 10A).  These lines 
were immortalized following the well-established 3T3 protocol developed by Todaro & 
Green in 1963.  Following immortalization cells were treated with 1μM 4-OHT for 72hrs 
to activate Cre-ERT2 to delete at loxP sites and to induce recombination to remove 
ADA3 and activate the GFP reporter (Figure 10B).  Ada3 protein is not expressed in 
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Figure 13.  Generation of Cre-ERT2 inducible deletion MEF cell lines. (A) Ten 
embryos were isolated and genotyped for Ada3, GFP, and Cre-ERT2 in conjunction 
with negative and positive controls for each gene.  (B) Immortalized MEFs 
heterozygous or homozygous for Ada3, and heterozygous for GFP and Cre-ERT2 were 




3.4 DISCUSSION AND FUTURE DIRECTIONS 
 Recently, the role of Ada3 in cell cycle progression and embryonic development 
has been determined to be highly important (Mohibi et al, 2012).  Deletion leads to 
embryos not surviving past day E8.5 (Mohibi et al, 2012).  Additionally, Ada3 has been 
found to function as a coactivator for the estrogen receptor and is overexpressed in 
breast cancer, leading to an increase in the levels of c-myc (Meng et al, 2004; Griffin et 
al, submitted).  The inducible deletion MEF cell lines generated can be used for future 
analysis of Ada3 mutants generated in the lab because deletion is complete, unlike the 
mosaic deletion seen when Cre-mediated gene deletion is performed using 
adenoviruses.  Our recent finding that high levels of nuclear Ada3 correlated with high 
levels of c-myc in ER+ breast cancer patients pushes us towards analyzing the interplay 
between Ada3 and c-myc in a breast cancer model system.  In order to determine the 
role of Ada3 in breast cancers we will breed our conditional deletion mice with the 
doxycycline inducible PIK3CA driven mammary tumor model mouse.  By transplanting 
the mammary gland from a Cre-ERT2+ mouse into a non Cre-ERT2 mouse we will be 
able to study the effects of Ada3 deletion on c-myc mediated tumor progression.  We 


















 Recent studies from our laboratory demonstrated the role of Ada3 led to cell 
cycle delays and that Ada3 functions as a prognostic marker in concert with hormone 
receptor status provided the rationale to examine the role of Ada3 overexpression in 
proliferation (Mohibi et al, 2012; Mirza et al, 2013).  After examining multiple breast 
cancer cell lines and tumors grown in vivo we were able to ascertain that when 
compared to immortal mammary cells, cancerous cells expressed a higher amount of 
Ada3 protein.  The increased Ada3 protein level also correlated with increased levels of 
Ki67, a well-known marker of proliferation, in PDX tumors.  Ada3 levels were also higher 
in ER+ samples as opposed to other subtypes.   Consequently, we chose to overexpress 
Ada3 in immortal mammary epithelial cells and ER+ breast cancer cell lines. 
 Upon overexpression of Ada3, we found a significant increase in cell proliferation 
in the immortal mammary epithelial cell lines and ER+ breast cancer cell lines.  These 
results were not wholly unexpected, because recent findings made by our laboratory 
demonstrated that deletion of Ada3 led to decreased proliferation (Mohibi et al, 2012).  
The well-known SRC3 coactivator has been shown to enhance proliferation when it is 
overexpressed (Louie et al, 2004).  This protein also promotes ER mediated gene 
transcription and interacts with the p300 and PCAF histone acetyltransferases (Lahusen 
et al, 2009).  However, observations from our laboratory and from the O’Malley 
laboratory have not demonstrated that Ada3 and SRC3 function together in the same 
complex.  In an attempt to discern if there were any chromosomal changes linked to 
overexpressing Ada3, we examined the karyotype of both 76NTERT vector and Ada3 
overexpressing cells.  The karyotype was not significantly altered in Ada3 
overexpressing cells as compared to vector cells.  Thus, the observed increased 
proliferation was not the byproduct of an unstable genome. 
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 We examined cell cycle related genes after both the overexpression and 
knockdown of Ada3 to determine if cell cycle alterations were the source of the 
proliferative change.  Using FACS analysis we found that increased cell cycle 
progression from the G1 phase into the S phase was shifted approximately four hours 
earlier in the overexpressing cells to 16hrs (26.6%) as opposed to 20hrs (24%) in vector 
cells.  Conversely, when Ada3 was knocked down the 12hr time point for scrambled 
control marked the beginning of the transition of cells into S phase, while that didn’t 
begin until the 16hr time point in KD cells.  Overall fewer cells were observed to be 
entering the cell cycle when Ada3 was ablated, much in the same way that was 
observed previously (Mohibi et al, 2012).   Interestingly, p27 levels were decreased 
during Ada3 overexpression and c-myc levels were increased.   It has been previously 
documented that c-myc deletion is embryonically lethal and that KD of Ada3 leads to a 
decrease in c-myc levels (Davis et al, 1993; Mohibi et al, 2012).  Similarly to the findings 
of Mohibi et al, Ada3 knockdown in immortal mammary epithelial cells led to a delay in 
phase transitions and an increase in p27 levels (2012).  Two well-known early cell cycle 
response genes, c-fos and EGR1, were found to have greatly increased mRNA levels in 
overexpressing cells as compared to vector.  C-fos has long been known to be involved 
in proliferation and EGR1 has also been found to be important for cell proliferation and 
migration (Angel & Karin, 1991; Mitchell et al, 2004; Min et al, 2008), therefore 
expression levels for both being elevated in our overexpressing cells makes sense.  
 As the mechanism governing cell cycle transition delays in MEFs is mediated by 
a mechanism containing both p27 and c-myc we examined the levels of these gene 
products.  When overexpressed, the levels of c-myc mRNA and protein are higher than 
that of vector cells, while the p27 half-life is decreased, again functioning in the opposite 
way of the knockdown studies performed previously (Mohibi et al, 2012).   Just as in 
previous studies, we observed a decrease in histone acetylation when Ada3 was 
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knocked down in human derived cell lines; however levels were increased when Ada3 
was overexpressed.  This increase makes sense in that for cells to become more 
proliferative there must be an increase in acetylated histones to allow DNA binding 
proteins access to DNA.    
 In attempt to build upon previous work from our lab showing Ada3 is an important 
ER coactivator (Meng et al, 2004; Germaniuk-Kurowska et al 2007) we scrutinized the 
effect of Ada3 overexpression on estrogen independence in ER+ breast cancer cell 
lines.  After depriving the commonly used MCF7 and ZR75-1 cell lines cells of growth 
factors other than estrogen and performing proliferation assays, we found no link 
between the levels of Ada3 expression and estrogen independent growth.  The 
overexpression cells exhibited proliferation similar to that of vector cells when deprived 
of estrogen.  Had this occurred we would have examined the components of the AKT 
pathway to determine if these were elevated to cause proliferation and growth (Miller et 
al, 2010).    We did find that the mRNA for ER target genes was increased post 
stimulation which was in line with the previous findings of our lab.  Additionally, the 
overexpressing cells proliferated at a greater rate than the vector cells when stimulated 
with estrogen, similar to the amount of proliferation seen in complete media so even with 
limited defined growth factors Ada3 can lead to increased proliferation.  Next we treated 
cell lines with varied doses of tamoxifen to determine if there was a link between Ada3 
and resistance as observed with SRC3 (Osborne et al, 2003; Shou et al, 2004; Dihge et 
al, 2008; Kamakar et al 2010).   We found no change in the survival of overexpressing 
cells when compared to vector cells. This is more than likely due to these coactivators 
functioning in the same manner, but in separate mutually exclusive complexes.  We then 
desired to ascertain if there was a change in the invasion and migration potential in both 
ER+ and ErbB2+ breast cancer cell lines overexpressing Ada3 as was observed using 
an SRC3 variant (Long et al, 2010.)  Again, we found no significant difference in these 
90 
 
measurements of oncogenic potential.  Due to the increased levels of Ada3 in tumor cell 
lines as opposed to immortal cell lines and that tumor tissues were observed to contain 
cytoplasmic Ada3, we examined 2D grown tumor cell lines for changes in localization.  
We found that during in vitro growth Ada3 is a nuclear protein.  This may be due to cells 
grown in culture lacking the specific microenvironment necessary to redistribute Ada3 to 
the cytoplasm as observed in patient samples.  We then examined the global changes 
caused by Ada3 overexpression in asynchronous 76NTERT cells through microarray 
analysis.  We found that there is a differential change in expression in the levels of 
multiple genes with some affected pathways akin to what was observed in MEFs.  Of the 
most potential interest are networks involving the regulation of the cell cycle; however 
the majority of these differentially regulated proteins were not within the standard range 
of greater than 1.5 fold change in expression levels.  Our analysis of these dysregulated 
pathways was not exhaustive, thus delving deeper into potential alternate mechanisms 
to the established Ada3-c-myc-Skp2-p27 pathway could be performed in the future.   
 The observed significant connection between nuclear Ada3 expression levels 
and nuclear c-myc levels in patient samples can be further examined to ascertain if there 
is an alteration in tumor burden when Ada3 is deleted in a mammary tumor model 
exhibiting c-myc amplification.  The findings of this study together with previous studies 
examining the role of Ada3 ablation in the cell cycle, the role of Ada3 in mitosis, and the 
effect of expression on cancer prognosis help to better emphasize the importance of 





 While I have attempted to thoroughly examine the role of Ada3 in proliferation 
and oncogenesis, there are still several important areas that need to be explored in the 
future.  These include, but are not limited to: 
- Examine E2F related transcription factors for alterations in expression level 
as an alternative or additional pathway to increased proliferation 
- Determine if there are novel Ada3 target genes in ER+ cell lines via ChIP   
- Examine the role of Ada3 in murine development using the Ada3FL/FL, GFP, 
Cre-ERT2 mice 
- Breed the  Ada3FL/FL, GFP, Cre-ERT2 mice with PIK3CA mice to allow for the 
deletion ofAda3  in the mammary gland and to observe  mice for altered 
tumor burden 
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